ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 942

Validity and Reliability of the Lupus Damage Index Questionnaire (LDIQ): A Prospective Study

Yuko Okamoto, Yasuhiro Katsumata, Yasushi Kawaguchi, Sayumi Baba, Kae Takagi, Hisae Ichida, Takahisa Gono, Masanori Hanaoka, Yuko Ota and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease II

Session Type: Abstract Submissions (ACR)

Background/Purpose: The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (ACR) Damage Index (SDI) is a validated instrument for assessing organ damage in systemic lupus erythematosus (SLE). Trained physicians must complete it, thus limiting utility where this is impossible. A self-administered questionnaire, modeled after the SDI, the Lupus Damage Index Questionnaire (LDIQ) has been previously developed and validated. It may allow the ascertainment of this construct in SLE patients followed in the community. The original English version of LDIQ was subsequently translated into Spanish, Portuguese and French. The purpose of the present study was to translate and adapt the LDIQ to Japanese and further investigate its validity and reliability using a prospective observational cohort of SLE patients followed at a single university clinic.

Methods: The English version of the LDIQ was translated, back-translated and culturally adapted to Japanese using standard methodology. Japanese SLE patients who had 4 or more revised ACR criteria for SLE were approached during their outpatient attendance in our university clinic. Some of the hospitalized patients during the study period were also eligible to the study. Patients were asked to complete the LDIQ and other related demographic questionnaires such as Medical Outcomes Study Short Form-36 (SF-36) and physicians were asked to complete the SDI and the SLE Disease Activity Index 2000 (SLEDAI-2K). Patients were prospectively followed for repeat assessment next year.

Results: A total of 250 patients and 30 physicians (all rheumatologists) participated. The acceptability of the LDIQ was high, with most of items having 100% response rate. The distribution of the LDIQ and SDI both skewed to the right. The median LDIQ score was 2 (range 0–12) and the median SDI score was 1 (range 0–9). The LDIQ had a substantial correlation with the SDI (Spearman’s ρ = 0.71, p < 0.001). Cohen's kappa coefficient, a statistical measure of agreement for qualitative items, between the individual SDI and LDIQ items varied between 0.07-1.00. The damage domains of the LDIQ were not associated with each other, which was reflected in low Cronbach’s alpha (0.53). The LDIQ showed poor correlation with the SLEDAI-2K, and mental component summary scores of the SF-36, but had moderate correlation with physical component summary scores of the SF-36 (Spearman’s ρ = -0.08, -0.11, and -0.41, respectively). Twenty-five patients with stable disease were asked to repeat the LDIQ after 2 weeks and the intraclass correlation coefficient was 0.85, which means good test–retest reliability. These figures come from the first year research and the second year gave similar results. The LDIQ demonstrated a good responsiveness: standardized response mean = 0.40 and effect size = 0.32 in patients with worsened SDI.

Conclusion: We have successfully translated, adapted and validated the Japanese version of the LDIQ. There is evidence of acceptable reliability and validity of the Japanese version of the LDIQ among Japanese patients with SLE. Our study provides evidence of the cross-cultural validity of this tool and can be used to assess SLE-related damage among Japanese patients with SLE.


Disclosure:

Y. Okamoto,
None;

Y. Katsumata,
None;

Y. Kawaguchi,
None;

S. Baba,
None;

K. Takagi,
None;

H. Ichida,
None;

T. Gono,
None;

M. Hanaoka,
None;

Y. Ota,
None;

H. Yamanaka,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validity-and-reliability-of-the-lupus-damage-index-questionnaire-ldiq-a-prospective-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology